|
|
|
Bind bile acids in the intestine, causing the acids to be excreted rather than used to make bile and causing the liver to remove more LDL cholesterol from the bloodstream to make bile
|
|
Binding of some other drugs (reducing their effectiveness)
Increase in triglyceride level (especially in people with high triglyceride levels)
|
Cholesterol absorption inhibitor
|
|
|
Decreases cholesterol absorption in the small intestine
|
|
Face and lip swelling (very rare)
|
|
|
|
Increase the breakdown of lipids and speed the removal of VLDL from the bloodstream
May decrease VLDL production by the liver
|
Possibly high VLDL cholesterol
|
Muscle aches due to inflammation (myositis)
|
Microsomal triglyceride transfer protein inhibitor
|
|
|
Inhibits triglyceride secretion
|
Familial hypercholesteremia in people who have 2 abnormal genes (are homozygous)
|
|
|
|
|
Lowers triglyceride levels
At high doses, decreases production rate of VLDL, which is used to synthesize LDL
|
High LDL and VLDL cholesterol
|
High blood sugar level (hyperglycemia)
|
Oligonucleotide inhibitor of apolipoprotein B
|
|
|
Lowers level of apolipoprotein B
|
Familial hypercholesteremia (homozygous)
|
Skin reactions at injection sites
|
|
|
|
Lower levels of triglycerides
May decrease production of VLDL
|
|
|
|
|
|
|
Familial hypercholesterolemia and for other people at high risk of coronary artery disease
|
Rarely, high liver enzyme levels
Skin reactions at injection sites
|
|
|
|
Familial hypercholesterolemia and for other people at high risk of coronary artery disease
|
Skin reactions at injection sites
|
Statins (HMG-CoA reductase inhibitors)
|
|
|
Block the synthesis of cholesterol, increasing the removal of LDL from the bloodstream
|
High LDL cholesterol, triglycerides, or both
|
Rarely, high liver enzyme levels
Rarely, muscle aches due to inflammation (myositis) or degeneration (rhabdomyolysis)
|
